Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management.

ABSTRACT:

Background

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) can change management in a large fraction of patients with biochemically recurrent prostate cancer (BCR).

Purpose

To investigate the added value of PET to MRI and CT for this patient group, and to explore whether the choice of the PET paired modality (PET/MRI vs. PET/CT) impacts detection rates and clinical management.

Study type

Retrospective.

Subjects

41 patients with BCR (median age [range]: 68 [55-78]).

Field strength/sequence

3T, including T1-weighted gradient echo (GRE), T2-weighted turbo spin echo (TSE) and dynamic contrast-enhanced GRE sequences, diffusion-weighted echo-planar imaging, and a T1-weighted TSE spine sequence. In addition to MRI, [¹⁸F]P

SUBMITTER: Abrahamsen BS 

PROVIDER: S-EPMC11645485 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature